334477-18-8

Usage

Uses

Used in Pharmaceutical Industry:
(+)-(S)-3-(4-fluoro-2-methylphenyl)-piperazin-2-one is used as a pharmaceutical intermediate for the development of drugs targeting neurological and psychiatric disorders. Its specific biological activities and potential therapeutic applications are still under investigation, making it a promising candidate for future drug discovery and development.
Used in Medicinal Chemistry Research:
(+)-(S)-3-(4-fluoro-2-methylphenyl)-piperazin-2-one serves as a valuable compound in medicinal chemistry research, where it can be used to study the structure-activity relationships of piperazinone derivatives. This knowledge can contribute to the design and synthesis of novel therapeutic agents with improved efficacy and selectivity.
Used in Drug Synthesis:
(+)-(S)-3-(4-fluoro-2-methylphenyl)-piperazin-2-one can be employed as a key building block in the synthesis of various pharmaceuticals. Its unique structure and chirality make it a versatile component in the development of enantioselective synthetic routes for the production of chiral drugs.

Upstream product

• 334477-72-4 (3S)-3-(4-fluoro-2-methylphenyl)-2-piperazinone (S)-mandelate 
• 334477-68-8 3-(4-fluoro-2-methylphenyl)-piperazin-2-one 
• 611-71-2 (R)-Mandelic Acid 
• 334477-07-5 (4-fluoro-2-methylphenyl)oxoacetic acid methyl ester 
• 334477-08-6 3-(4-fluoro-2-methylphenyl)-5,6-dihydro-1H-pyrazin-2-one 

Relevant academic research and scientific papers

Iridium-Catalyzed Asymmetric Hydrogenation of Unsaturated Piperazin-2-ones

Two different iridium catalyst systems, generated from the ruthenocene-based phosphine-oxazoline ligand tBu-mono-RuPHOX or the diphosphine ligand BINAP, were developed for the asymmetric hydrogenation of 5,6-dihydropyrazin-2(1H)-ones, affording chiral piperazin-2-ones in good yields and with moderate to good ees. Different catalytic behaviors for the hydrogenation of these types of substrate were observed with these two catalyst systems. Our tBu-mono-RuPHOX ligand, which bears a ruthenocene scaffold with planar chirality, was found to be the best ligand for the [Ir(L)(COD)]BArF catalyst system, affording the desired products with up to 94% ee. (Figure presented.).

Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis- trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor

In an effort to discover novel druglike NK1 receptor antagonists a new series of suitably substituted C-phenylpiperazine derivatives was identified by an appropriate chemical exploration of related N-phenylpiperazine analogues, with the specifi